Regular use of low-dose aspirin may reduce the overall risk of developing certain cancers such as colon and gastrointestinal tumors by 3%, a recent study suggests. Nevertheless, the benefit has appeared only after six years of daily aspirin use.
As an anti-inflammatory drug, aspirin has undeniable effect of certain molecular pathways that are associated with cancer. Aspirin suppress inflammation and certain carcinogenic proteins to some extent on the long run.
The study found 3% lower risk of overall cancer, and 15% lower risk for gastrointestinal cancer and 19% reduced risk of developing colon and rectum cancers. However, low-dose aspirin does not reduce the risk of other cancers such as lung, breast and prostate cancers.
The study results appear in the journal JAMA Oncology.